Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
NCT ID: NCT02467634
Last Updated: 2016-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
3 participants
INTERVENTIONAL
2015-06-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03834753
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
NCT00436553
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
NCT02510794
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
NCT02358889
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
NCT02484690
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HuCNS-SC
HuCNS-SC sub-retinal transplantation
HuCNS-SC sub-retinal transplantation
HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HuCNS-SC sub-retinal transplantation
HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BCVA of 20/320 or better in each eye at screening assessment
Exclusion Criteria
* Retinal or macular disease of any other cause in either eye.
* Diagnosis of glaucoma in either eye.
* Uncontrolled intraocular pressure in either eye
* Compromised renal function defined as eGFR \<60mL/min and urine protein-to-creatinine ration \>0.3 is spot urine collection.
* History of or active autoimmune disease.
* Previous organ, tissue or bone marrow transplantation.
* Seropositive for HIV, hepatitis B or C, or CMV IgM
50 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
StemCells, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joel Naor, MD
Role: STUDY_CHAIR
StemCells, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Associates Southwest, PC
Tucson, Arizona, United States
Retina Vitreous Associates Medical Group
Beverly Hills, California, United States
Retinal Diagnostic Center
Campbell, California, United States
Northern California Retina Vitreous Associates
Mountain View, California, United States
Retina Research Institute of Texas
Palo Alto, California, United States
Rush University Med Ctr.
Chicago, Illinois, United States
William Beaumont Health System
Royal Oak, Michigan, United States
New York Eye and Ear Infirmary
New York, New York, United States
Retina Research Institute of Texas
Abilene, Texas, United States
Retina Research Center
Austin, Texas, United States
Retina Foundation of the Southwest
Dallas, Texas, United States
University Of Utah / John A. Moran Eye Center
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL-AMD-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.